Vera Therapeutics, Inc. $VERA Stock Bought by Candriam S.C.A.

Candriam S.C.A. grew its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 21.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 568,560 shares of the company’s stock after acquiring an additional 100,461 shares during the period. Candriam S.C.A.’s holdings in Vera Therapeutics were worth $18,426,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Pictet Asset Management Holding SA boosted its stake in shares of Vera Therapeutics by 47.2% during the 3rd quarter. Pictet Asset Management Holding SA now owns 1,839,245 shares of the company’s stock worth $59,397,000 after acquiring an additional 589,831 shares in the last quarter. Readystate Asset Management LP acquired a new stake in shares of Vera Therapeutics in the 2nd quarter worth approximately $12,663,000. Renaissance Technologies LLC grew its holdings in shares of Vera Therapeutics by 136.5% in the 1st quarter. Renaissance Technologies LLC now owns 457,300 shares of the company’s stock worth $18,397,000 after acquiring an additional 263,900 shares during the period. Engineers Gate Manager LP increased its stake in Vera Therapeutics by 1,579.2% in the 2nd quarter. Engineers Gate Manager LP now owns 108,139 shares of the company’s stock valued at $4,640,000 after purchasing an additional 101,699 shares in the last quarter. Finally, Squarepoint Ops LLC increased its stake in Vera Therapeutics by 569.1% in the 2nd quarter. Squarepoint Ops LLC now owns 104,937 shares of the company’s stock valued at $4,503,000 after purchasing an additional 89,253 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 18,500 shares of the stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $37.00, for a total transaction of $684,500.00. Following the sale, the chief executive officer owned 235,244 shares in the company, valued at approximately $8,704,028. This represents a 7.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 15.90% of the company’s stock.

Analyst Upgrades and Downgrades

VERA has been the subject of several research reports. JPMorgan Chase & Co. lifted their price objective on Vera Therapeutics from $76.00 to $83.00 and gave the stock an “overweight” rating in a report on Tuesday, September 8th. Wall Street Zen raised Vera Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday. Guggenheim dropped their price target on Vera Therapeutics from $76.00 to $66.00 and set a “buy” rating for the company in a research report on Friday. TD Cowen restated a “buy” rating on shares of Vera Therapeutics in a research report on Tuesday, September 15th. Finally, Leerink Partners began coverage on Vera Therapeutics in a research note on Monday, October 12th. They set a “market perform” rating and a $34.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $74.93.

Key Headlines Impacting Vera Therapeutics

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: For Q3 2026, Vera reported a loss of $1.30 per share, narrower than the $1.62 consensus loss, and revenue of $10.28 million versus estimates of $3.42 million. The earnings beats are supportive, although the company remained loss-making. Quarterly earnings report
• Positive Sentiment: HC Wainwright cut its price target to $75 from $90 but maintained a Buy rating. Its revised target still implies substantial upside from the cited $29.79 share price, which may offer support to investors. HC Wainwright rating update
• Neutral Sentiment: Vera granted stock options covering 14,900 shares and restricted stock units covering 7,450 shares to three new employees. The awards are a routine hiring incentive, with a small potential dilution effect. Inducement grants announcement
• Negative Sentiment: A valuation-focused article argues VERA may be above fair value after a 148% run, raising the risk that investors take profits or demand stronger progress to justify the share price. Valuation analysis
• Negative Sentiment: Although HC Wainwright remains bullish, its $15 reduction in the target reflects a more cautious view than before and may temper optimism. HC Wainwright rating update

Vera Therapeutics Stock Down 0.0%

Shares of NASDAQ VERA opened at $29.78 on Monday. The firm’s 50-day moving average is $31.60 and its two-hundred day moving average is $36.68. The company has a market capitalization of $2.15 billion, a PE ratio of -5.05 and a beta of 1.07. Vera Therapeutics, Inc. has a 12-month low of $23.86 and a 12-month high of $56.05. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.92.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($1.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.62) by $0.32. The business had revenue of $10.28 million for the quarter, compared to analysts’ expectations of $3.42 million. Equities analysts anticipate that Vera Therapeutics, Inc. will post -6.45 EPS for the current fiscal year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immunological diseases. The company’s research is centered on therapies that target the underlying causes of autoimmune conditions rather than primarily addressing their symptoms.

Vera’s lead product candidate is atacicept, a biologic designed to inhibit the B-cell survival factors BLyS and APRIL. The company has been evaluating atacicept in IgA nephropathy, an autoimmune kidney disease that can lead to progressive loss of kidney function, and has also investigated its potential in other immune-mediated diseases.